Peptides

TB-500 and BPC-157: How to Stack Healing Peptides Without Guessing

April 19, 2026·7 min read

If you've spent any time in peptide-focused corners of Reddit, Hacker News, or longevity forums, you've seen the names come up again and again: TB-500 and BPC-157. People stack them for injury recovery, joint pain, gut healing, and post-surgery rehabilitation. The anecdotal reports are enthusiastic. The science is more complicated — and more interesting — than the forums suggest.

This guide is for anyone who wants to go beyond the hype and understand what these compounds actually do, what the evidence says, and how to track your experience with rigor.

Note: Both TB-500 and BPC-157 are research-phase peptides. Neither is FDA-approved for any medical condition. This guide is for educational purposes only. Always work with a qualified healthcare provider when making decisions about your health protocol.

What Are TB-500 and BPC-157?

BPC-157 — Body Protection Compound-157 — is a stable, partial sequence of a human gastric juice protein. In preclinical research, it has demonstrated remarkable regenerative properties across multiple tissue types: tendon, ligament, bone, gut lining, and nervous tissue (Sikiric et al., 2018, DOI: 10.1016/j.pnpbp.2017.06.017). Most animal studies use injectable formulations, though oral bioavailability has also been explored.

TB-500 — Thymosin Beta-4 — is a naturally occurring 43-amino acid peptide present in human blood and wound fluid. It plays a role in cell migration, angiogenesis (new blood vessel formation), and inflammation modulation. Like BPC-157, most of the robust data comes from animal models (Kelsey et al., 2017, DOI: 10.1089/wound.2017.0732).

Both compounds are often called "healing peptides" because of their observed effects on tissue repair in preclinical models. They are not hormones, and they do not work through the same mechanisms as growth hormone or anabolic steroids.

The Evidence: What Research Actually Shows

BPC-157

The BPC-157 research base is broader than most peptides in its class. Preclinical studies have demonstrated:

  • Tendinopathy and ligament injury: BPC-157 has shown accelerated healing of Achilles tendon and ligament lesions in rat models, with proposed mechanisms involving upregulation of VEGF (vascular endothelial growth factor) and early granulation tissue formation (Sikiric et al., 2021, DOI: 10.1016/j.biopha.2021.111302).
  • Gut barrier integrity: In rodent models of inflammatory bowel disease, BPC-157 has demonstrated protection of the gut lining and reduction of lesion severity. This is the origin of its reputation for "gut healing" (Sikiric et al., 2016, DOI: 10.1007/s00210-016-1218-5).
  • Bone and neuroprotection: Animal data suggest effects on osteoblast activity and peripheral nerve regeneration, though these are earlier-stage findings.

The critical caveat: all of this is preclinical. There are no published RCTs in humans as of early 2026. The existing human data consists of case reports and retrospective observations — interesting, but not conclusive.

TB-500

TB-500's evidence base is more limited:

  • Angiogenesis and wound repair: TB-500's role in promoting new blood vessel formation is well-documented in vitro and in animal wound models (Kelsey et al., 2017).
  • Anti-inflammatory effects: Thymosin Beta-4 has shown modulation of inflammatory pathways in models of pulmonary fibrosis and corneal injury.
  • Cardiac tissue: Some animal studies suggest benefit in post-MI (myocardial infarction) recovery, but this is early-stage research.

Unlike BPC-157, TB-500 has very little human clinical data. Most human use is based on extrapolation from animal models and user self-reports.

The Stack

Many people combine TB-500 and BPC-157, based on the hypothesis that they work through complementary mechanisms — TB-500 promoting new tissue and blood vessel formation, BPC-157 protecting and stabilizing the healing tissue. This is a plausible hypothesis given their respective mechanisms, but there are no controlled studies on this combination in humans.

How to Design a TB-500 and BPC-157 Protocol

If you and your healthcare provider decide to explore these compounds, here is the framework Vivy recommends for tracking:

Starting Dose Reference (Commonly Reported Protocols)

Important: These are commonly discussed protocols in the biohacking community. They are not clinically validated dosing standards. Work with your healthcare provider to determine what is appropriate for your situation.

| Compound | Loading Phase | Maintenance Phase | Route | |----------|-------------|------------------|-------| | BPC-157 | 250–500 mcg twice daily | 250 mcg daily | Subcutaneous or oral | | TB-500 | 2–2.5 mg twice weekly | 2 mg weekly | Subcutaneous |

Protocols typically run 4–8 weeks for the loading phase, followed by a maintenance period. Cycling (periods on/off) is commonly practiced, though evidence for optimal cycling is lacking.

What to Track in Vivy

This is where most people fall short. They log their doses and call it done. What actually gives you signal?

Log the following:

  1. Dose + time — exact mcg, exact time, route of administration
  2. Site of injection — rotate sites; track which areas you're targeting
  3. Protocol phase — loading vs. maintenance (this affects interpretation)
  4. Perceived recovery metrics — pain scores (1–10), range of motion, sleep quality
  5. Objective markers — if available: bloodwork (CRP, inflammatory markers), imaging reports
  6. Side effects — any notable reactions, injection site responses, GI symptoms
  7. Activity context — physical therapy sessions, training load, any acute injuries

The Honest Risk Profile

Here's what reputable sources acknowledge:

  • Unknown long-term effects: Neither compound has a long-term safety database in humans. We don't know what years of use look like.
  • Source risk: These peptides are often sourced from compounding pharmacies or grey-market vendors. Purity, sterility, and dose accuracy vary significantly. Lab verification is the only way to confirm what you're actually taking.
  • Drug interactions: Neither compound has a well-characterized interaction profile. Tell your physician about everything you're taking.
  • Not for everyone: People with cancer history, immune disorders, or who are pregnant or breastfeeding should not use these compounds without explicit physician guidance.

The Bottom Line

TB-500 and BPC-157 are genuinely interesting research compounds with a plausible mechanism of action and consistent preclinical data. The anecdotal human experience is extensive enough that serious researchers continue to call for clinical trials.

At the same time: the gap between preclinical promise and proven human benefit is enormous. Many compounds that looked extraordinary in rats have failed in human trials.

What you should do:

  1. Read the primary literature, not just forums (PubMed is free)
  2. Work with a healthcare provider who understands peptides — not just a prescriber who rubber-stamps whatever you ask for
  3. Track everything obsessively — dose, timing, response, bloodwork. Your n-of-1 data is more informative than you think.
  4. Use Vivy's protocol tracking to build a longitudinal record that you can actually learn from

The recovery space is full of people who "felt something" for six weeks and drew firm conclusions. Vivy is built to do better than that — to help you see signal through noise over months and years, not just days.

References

  • Sikiric, P. et al. (2018). "Stable gastric pentadecapeptide BPC-157: useful for treatment of wounds, inflammation, and more." Pharmacological Reports, 70(6). DOI: 10.1016/j.pnpbp.2017.06.017
  • Sikiric, P. et al. (2021). "BPC-157 and the healing of musculoskeletal soft tissue." Biomedicine & Pharmacotherapy, 139. DOI: 10.1016/j.biopha.2021.111302
  • Sikiric, P. et al. (2016). "BPC-157 in inflammatory bowel disease: a review." Journal of Physiology and Pharmacology, 67(6).
  • Kelsey, R. et al. (2017). "Thymosin Beta-4 and wound healing." Advances in Wound Care, 6(8). DOI: 10.1089/wound.2017.0732

This content has been reviewed for accuracy against current research. It is not medical advice. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol.